H2052 and H513 are human mesothelioma cell lines originated from pleural effusion from the American Type Culture Collection (ATCC, Manassas, VA; www.atcc.org). and Vero (African green monkey kidney; obtained from D. The digested tissue was strained with a 40-μm strainer, the cell suspension was washed with PBS and the red blood cells were lysed. For combination therapy, cells were seeded into a 10-cm culture dish and infected with viruses at a MOI of 0.5, 1 nM paclitaxel (Sigma), G47Δ + paclitaxel or a mock treatment. 686, 1483 and U373 cells were grown in DMEM F-12 medium. (DRH), and the National Institutes of Health P50 CA097247 and P01 CA71933 (JMM). It is based on the model of multiple cycles of lytic virus replication in cancer cells that amplify the injected dose.
This approach has been largely unsuccessful (reviewed in Miyatake et al.12). Though still rare, the risk of HSE may be increased in patients with cancer, especially in those receiving cranial RT. While no adverse effects occurred, there was cancer cell death and 30-100% regression histopathologically in recurrent breast cancer. In vivo, the intraneoplastic inoculation of G207 induced a significant inhibition of the tumor growth. In all cases, areas of necrosis also strongly stained for HSV. Foreskin-derived fibroblasts (obtained from Dr Zhang Qi, Department of Hepatic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, China) that were isolated as previously described were cultured in 1640 medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) at 37 °C in 5% CO2.22 G47Δ was constructed as described previously.16 The virus was grown and titered on Vero cells (African green monkey kidney; ATCC, Manassas, VA, USA) in DMEM with glucose (4.5 g l−1) supplemented with 10% calf serum at 37 °C in 5% CO2. The authors concluded that this principle of miRNA-based regulation of viral replication could be a useful tool to target cancer cells selectively and prevent normal tissues from viral damage.
In experimental models of PDAC, mice receiving intratumoral Myb34.5 injections appeared healthy and tumor progression was inhibited, with evidence of tumor necrosis, hemorrhage, viral replication, and cancer cell death by apoptosis. Prelim-inary work suggests that combined immunostimulatory and oncolytic therapy enhances tumor cell kill.33 In the present experiments, NV1042, a replication competent, oncolytic HSV expressing IL-12, was used to treat established hepatic tumors prior to resection. To prolong the anti-tumor effect some mice were also given cyclophosphamide, hydrocortisone, or a second injection of virus. RESULTS: Infection of DU145, PC3 and LNCaP cells with DISC-HSV was dose dependent. Inhibitors of class I HDACs, including pan-selective compounds, were more effective for increasing oHSV replication compared to inhibitors that selectively target class II HDACs. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. The results do not support the hypothesis that HSV-2 is an etiologic agent for cervical neoplasia.
Human Gene Therapy. We reasoned that both fusogenic strategies, incorporated into a single oncolytic HSV, might significantly improve virotherapy for ovarian cancer. This antitumor effect was significantly greater than with a lacZ-defective/replication-competent HSV vector combination, which itself was significantly greater than the mock inoculation. Typical, self-limited orolabial or genital ulceration does not always require laboratory diagnosis or treatment, but HSV may present in an atypical fashion in cancer patients and cause more severe and prolonged mucocutaneous infection or visceral disease. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. GCV killing of Ad.HSV-tk, Ad.dm30-tk and Ad.sr39-tk was assessed in various tumor cell lines with a cell proliferation assay. Top of pageMaterials and methodsCells The human breast cancer cell lines, monocyte chemoattractant factor-7 (MCF-7) and MDA-MB-231, were kindly provided by Dr Y Wang (SUNY Upstate Medical University, Syracuse, NY) and Dr S Taffet (SUNY Upstate Medical University), respectively.
To cite this article: Masahiro Toda, Samuel D. A Kanzaki1, H Kasuya1, K Yamamura1, T T Sahin1, N Nomura1, T Shikano1, T Shirota1, G Tan1, S Fukuda1, M Misawa1, Y Nishikawa1, S Yamada1, T Fujii1, H Sugimoto1, S Nomoto1, S Takeda1, Y Kodera1 and A Nakao1 Top of pageIntroduction Colorectal cancer is the most common cancer of the digestive tract.1, 2 To date, all studies on peritoneal carcinomatosis from colorectal cancer have shown that there is a high incidence of abdominal dissemination in patients with a poor prognosis; such patients have a median survival of 5−9 months.2, 3, 4 This observation clearly indicates the importance of treating peritoneal dissemination in colorectal cancer patients.